- Home
- HCC vs NAMS Comparison
HCC vs NAMS Comparison
Compare HCC & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HCC | NAMS |
|---|---|---|
| Founded | 2015 | 2019 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Coal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 3.1B |
| IPO Year | 2017 | N/A |
Fundamental Metrics
Financial Performance| Metric | HCC | NAMS |
|---|---|---|
| Price | $80.56 | $35.81 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 10 |
| Target Price | ★ $73.50 | $45.80 |
| AVG Volume (30 Days) | 681.3K | ★ 1.1M |
| Earning Date | 11-05-2025 | 11-05-2025 |
| Dividend Yield | ★ 0.40% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.67 | N/A |
| Revenue | ★ $1,224,320,000.00 | $35,243,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $46.92 | N/A |
| P/E Ratio | $120.01 | ★ N/A |
| Revenue Growth | N/A | ★ 4.91 |
| 52 Week Low | $38.00 | $14.06 |
| 52 Week High | $85.86 | $42.00 |
Technical Indicators
Market Signals| Indicator | HCC | NAMS |
|---|---|---|
| Relative Strength Index (RSI) | 58.74 | 44.80 |
| Support Level | $78.00 | $34.59 |
| Resistance Level | $84.77 | $36.60 |
| Average True Range (ATR) | 2.91 | 1.91 |
| MACD | -0.20 | -0.64 |
| Stochastic Oscillator | 67.90 | 15.64 |
Price Performance
Historical ComparisonAbout HCC Warrior Met Coal Inc.
Warrior Met Coal Inc is a U.S based company. It produces and exports of met coal that operates underground mines in Alabama. The company sells to steels manufacturers in Europe, Asia, and South America. Its mining operations consist of two underground met coal mines in Southern Appalachia's coal seam and other surface met and thermal coal mines. The Company generates ancillary revenues from the sale of natural gas extracted as a byproduct from the underground coal mines and royalty revenues from leased properties.
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.